Jason Douglas Wilson Sells 4,000 Shares of Reata Pharmaceuticals Inc (RETA) Stock

Reata Pharmaceuticals Inc (NASDAQ:RETA) CFO Jason Douglas Wilson sold 4,000 shares of the business’s stock in a transaction dated Friday, February 15th. The shares were sold at an average price of $85.44, for a total value of $341,760.00. Following the completion of the transaction, the chief financial officer now directly owns 4,000 shares of the company’s stock, valued at approximately $341,760. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Jason Douglas Wilson also recently made the following trade(s):

  • On Tuesday, February 5th, Jason Douglas Wilson sold 3,000 shares of Reata Pharmaceuticals stock. The shares were sold at an average price of $80.00, for a total value of $240,000.00.
  • On Friday, February 1st, Jason Douglas Wilson sold 7,000 shares of Reata Pharmaceuticals stock. The shares were sold at an average price of $80.00, for a total value of $560,000.00.
  • On Tuesday, January 15th, Jason Douglas Wilson sold 4,000 shares of Reata Pharmaceuticals stock. The shares were sold at an average price of $71.15, for a total value of $284,600.00.
  • On Monday, January 7th, Jason Douglas Wilson sold 20,000 shares of Reata Pharmaceuticals stock. The shares were sold at an average price of $72.04, for a total value of $1,440,800.00.

NASDAQ:RETA traded down $0.99 during mid-day trading on Tuesday, reaching $85.37. 8,323 shares of the company were exchanged, compared to its average volume of 224,459. Reata Pharmaceuticals Inc has a 12 month low of $19.31 and a 12 month high of $99.50. The company has a quick ratio of 6.04, a current ratio of 6.04 and a debt-to-equity ratio of 2.10. The firm has a market cap of $2.57 billion, a P/E ratio of -43.09 and a beta of 3.15.

RETA has been the subject of a number of analyst reports. ValuEngine raised Reata Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, February 4th. Cantor Fitzgerald set a $100.00 target price on shares of Reata Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, November 7th. BidaskClub raised shares of Reata Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, February 13th. Finally, Zacks Investment Research lowered shares of Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, November 28th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the stock. Reata Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $100.33.

A number of large investors have recently modified their holdings of the business. Lindbrook Capital LLC bought a new position in shares of Reata Pharmaceuticals in the fourth quarter valued at $42,000. Tower Research Capital LLC TRC increased its stake in Reata Pharmaceuticals by 276.8% in the 3rd quarter. Tower Research Capital LLC TRC now owns 1,398 shares of the company’s stock worth $114,000 after purchasing an additional 1,027 shares during the period. Meeder Asset Management Inc. increased its stake in Reata Pharmaceuticals by 60.9% in the 4th quarter. Meeder Asset Management Inc. now owns 1,469 shares of the company’s stock worth $82,000 after purchasing an additional 556 shares during the period. Lee Financial Co purchased a new position in Reata Pharmaceuticals in the 3rd quarter worth approximately $128,000. Finally, Great West Life Assurance Co. Can increased its stake in Reata Pharmaceuticals by 125.7% in the 4th quarter. Great West Life Assurance Co. Can now owns 2,031 shares of the company’s stock worth $110,000 after purchasing an additional 1,131 shares during the period. 52.96% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: “Jason Douglas Wilson Sells 4,000 Shares of Reata Pharmaceuticals Inc (RETA) Stock” was published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.com-unik.info/2019/02/19/jason-douglas-wilson-sells-4000-shares-of-reata-pharmaceuticals-inc-reta-stock.html.

About Reata Pharmaceuticals

Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases with therapies by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl for the treatment of patients with chronic kidney disease caused by Alport syndrome; and for a form of pulmonary arterial hypertension associated with connective tissue disease.

See Also: The Discount Rate – What You Need to Know

Insider Buying and Selling by Quarter for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit